Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWO Study
2017-001421-41Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of TCK-276 in kidney transplant immunosuppression (2 arms), sponsored by University of Oxford. Primary endpoint: Incidence of biopsy-confirmed acute rejection. Status: unknown.
02
Drugs
TCK-276
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on 2017-001421-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001421-41.